| scholarly article | Q13442814 |
| P356 | DOI | 10.1002/JCLA.1860090209 |
| P698 | PubMed publication ID | 7536238 |
| P50 | author | Eleftherios P. Diamandis | Q37383505 |
| P2093 | author name string | H Hu | |
| M Levesque | |||
| M D'Costa | |||
| P2860 | cites work | Colonic neoplasms: tissue estrogen receptor and carcinoembryonic antigen | Q45356384 |
| P433 | issue | 2 | |
| P921 | main subject | hematology | Q103824 |
| medical laboratory technology | Q28119945 | ||
| P304 | page(s) | 123-128 | |
| P577 | publication date | 1995-01-01 | |
| P1433 | published in | Journal of Clinical Laboratory Analysis | Q15754724 |
| P1476 | title | Prostate-specific antigen expression by various tumors | |
| P478 | volume | 9 |
| Q73150613 | A peptide-doxorubicin 'prodrug' activated by prostate-specific antigen selectively kills prostate tumor cells positive for prostate-specific antigen in vivo |
| Q39234684 | A risk-adjusted definition of biochemical recurrence after radical prostatectomy |
| Q39418149 | Advances in Prostate-Specific Antigen Testing |
| Q57107671 | Approaches to the discovery of non-invasive urinary biomarkers of prostate cancer |
| Q40861646 | Breast cancer prognostic significance of a single nucleotide polymorphism in the proximal androgen response element of the prostate specific antigen gene promoter |
| Q74094402 | Clinical usefulness of RT-PCR detection of hematogenous prostate cancer spread |
| Q77380302 | Comparison of human prostate specific glandular kallikrein 2 and prostate specific antigen gene expression in prostate with gene amplification and overexpression of prostate specific glandular kallikrein 2 in tumor tissue |
| Q40466420 | Construction of tumor-specific toxins using ubiquitin fusion technique. |
| Q41297571 | Detection and characterization of the prostate‐specific membrane antigen (PSMA) in tissue extracts and body fluids |
| Q47751202 | Detection of disseminated prostate cells by reverse transcription-polymerase chain reaction (RT-PCR): technical and clinical aspects |
| Q71838585 | Detection of nonprostatic PSA in serum and nonserum samples from women |
| Q44182230 | Determination of a peptide-doxorubicin, prostate-specific antigen activated prodrug, and its active metabolites in human plasma using high-performance liquid chromatography with fluorescence detection. Stabilization of the peptide prodrug with EDTA. |
| Q37336885 | Different altered stage correlative expression of high abundance acute-phase proteins in sera of patients with epithelial ovarian carcinoma |
| Q36408671 | Does Rigid Cystoscopy Affect the Total Serum Prostate-Specific Antigen Levels? |
| Q34132863 | Drug-targeting strategies in cancer therapy |
| Q73435411 | ELISA for a complexed antigen with a monoclonal antibody blocking reaction with the free antigen-assay-specific for complexed prostate-specific antigen |
| Q26828563 | Emerging PSA-based tests to improve screening |
| Q35838103 | Enzymatic activity of free-prostate-specific antigen (f-PSA) is not required for some of its physiological activities |
| Q36618953 | Expression of prostate-specific antigen (PSA) correlates with poor response to tamoxifen therapy in recurrent breast cancer |
| Q50873161 | Free/Total Serum Prostate-Specific Antigen Ratio in Women with Colorectal Cancer Has Prognostic Significance. |
| Q57943390 | Frequent detection of mutations in the 5' flanking region of the prostate-specific antigen gene in female breast cancer |
| Q41090411 | Human tumor antigens are ready to fly. |
| Q34229832 | Identification of colorectal cancer related genes with mRMR and shortest path in protein-protein interaction network |
| Q36081213 | Immunofluorometric analysis of p53 protein and prostate-specific antigen in breast tumours and their association with other prognostic indicators |
| Q43785975 | Immunohistochemical analysis of prostate specific antigen in breast cancer |
| Q52958555 | Improving the Specificity of the Prostate-Specific Antigen Substrate Glutaryl-Hyp-Ala-Ser-Chg-Gln as a Promoiety. |
| Q71542437 | Kallikreins expression in a mature cystic ovarian teratoma |
| Q36643689 | Measurement of serum total and free prostate-specific antigen in women with colorectal carcinoma |
| Q36431227 | Molecular forms of prostate-specific antigen in the serum of women with benign and malignant breast diseases |
| Q57943425 | NONPROSTATIC SOURCES OF PROSTATE-SPECIFIC ANTIGEN |
| Q41409581 | New diagnostic applications of prostate-specific antigen |
| Q34939111 | New serum biomarkers for prostate cancer diagnosis |
| Q35609528 | PSA markers in prostate cancer detection |
| Q80295934 | Peripheral blood rt-PCR assays for detection and prognosis of prostate cancer |
| Q73583223 | Positive prostate-specific antigen circulating cells detected by reverse transcriptase-polymerase chain reaction does not imply the presence of prostatic micrometastases |
| Q34293280 | Positive resection margins may not reflect the true margin in patients undergoing radical prostatectomy |
| Q45929122 | Prostate specific antigen in women with menstrual disturbances and fibrocystic mastopathy. |
| Q57943178 | Prostate specific antigen molecular forms in breast cyst fluid and serum of women with fibrocystic breast disease |
| Q57082655 | Prostate specific antigen — a new constituent of breast cyst fluid |
| Q41192379 | Prostate-specific antigen in breast cyst fluid: possible role of prostate-specific antigen in hormone-dependent breast cancer |
| Q41051526 | Prostate-specific antigen induction by a steroid hormone in T47D cells growing in SCID mice |
| Q41409507 | Prostate-specific antigen, clinical use and staging: an overview |
| Q60367836 | Prostate-specific markers to identify rare prostate cancer cells in liquid biopsies |
| Q73875569 | Purification and characterization of prostate specific antigen from human urine |
| Q40795386 | Real-Time quantitative reverse transcriptase-polymerase chain reaction (RT-PCR) for the measurement of prostate-specific antigen mRNA in the peripheral blood of patients with prostate carcinoma using the taqman detection system. |
| Q42508371 | Regulation of prostate-specific antigen (PSA) gene expression and release in LNCaP prostate cancer by antagonists of growth hormone-releasing hormone and vasoactive intestinal peptide |
| Q101557486 | Surface receptor-mediated targeted drug delivery systems for enhanced cancer treatment: A state-of-the-art review |
| Q33884420 | The diagnostic and prognostic utility of prostate-specific antigen for diseases of the breast. |
| Q36619043 | The promoter and the enhancer region of the KLK 3 (prostate specific antigen) gene is frequently mutated in breast tumours and in breast carcinoma cell lines |
| Q34447102 | The role of molecular forms of prostate-specific antigen (PSA or hK3) and of human glandular kallikrein 2 (hK2) in the diagnosis and monitoring of prostate cancer and in extra-prostatic disease. |
| Q34394012 | The value of current diagnostic tests in prostate cancer screening |
Search more.